

26 June 2023

Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Dr Simon Sinclair, Non-Executive Director has purchased ordinary shares in the Company, as detailed below:

Number of Ordinary Shares	Average Price Paid Per Share	Total Consideration Paid
35,921	6.93 pence	£2,499.97

Following the above purchase of shares, Dr Simon Sinclair holds an interest in 96,336 Company ordinary shares and 300,000 warrants.

-ENDS-

Enquiries:

Roquefort Therapeutics plc

Stephen West (Chairman) / Ajan Reginald (CEO) +44 (0)20 3918 8633

Hybridan LLP (Joint Broker)

Claire Louise Noyce +44 (0)203 764 2341

Optiva Securities Limited (Joint Broker)

Christian Dennis +44 (0)20 3411 1881

Buchanan (Public Relations)

Ben Romney / Jamie Hooper / George Beale +44 (0)20 7466 5000

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics with novel anti-cancer approach;
- STAT-6 siRNA therapeutics targeting solid tumours with significant *in vivo* efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Simon Sinclair	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Roquefort Therapeutics plc	
b)	LEI	254900P4SISIWOR9RH34	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Ordinary shares of £0.01 par value	
	Identification code	ISIN: GB00BMDQ2T15	
b)	Nature of the transaction	Purchase of 35,921 ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		6.93 pence per share	35,921
d)	Aggregated information		
	- Aggregated volume	-	35,921
	- Price	-	6.93p
e)	Date of the transactions	26 June 2023	
f)	Place of the transactions	London Stock Exchange (XLON); Main Market	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBXGDLGSDDGXL

Anonymous (not verified)

Director/PDMR Shareholding

33597574

A

Mon, 06/26/2023 - 14:41

LSE RNS

Directors' Dealings

ROQ